EE351 Cost-Utility Analysis of Sequential Therapy of iCT IRd and DRd strategy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant-Ineligible in China

Uloženo v:
Podrobná bibliografie
Vydáno v:Value in health Ročník 28; číslo 6; s. S126 - S127
Hlavní autoři: Zuo, Genyong, Gao, Yongbo, Chen, Wendong, Chen, Wenming
Médium: Journal Article
Jazyk:angličtina
Vydáno: Elsevier Inc 01.07.2025
Témata:
Internal Medicine
Public Health
ISSN:1098-3015
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Author Zuo, Genyong
Gao, Yongbo
Chen, Wenming
Chen, Wendong
Author_xml – sequence: 1
  givenname: Genyong
  surname: Zuo
  fullname: Zuo, Genyong
  organization: Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine Shandong University, Jinan, China
– sequence: 2
  givenname: Yongbo
  surname: Gao
  fullname: Gao, Yongbo
  organization: Medical Affairs, Takeda (China) International Trading Company, HEOR Associate Manager, Beijing, China
– sequence: 3
  givenname: Wendong
  surname: Chen
  fullname: Chen, Wendong
  organization: Institute of Hospital Management Research, Xiangya Hospital of Central South University, Changsha, China
– sequence: 4
  givenname: Wenming
  surname: Chen
  fullname: Chen, Wenming
  organization: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China
BookMark eNqFkd1u1DAQhXNRJPrDE3DjF0gYO5s_IZCqdAsrtYDoVlxaE2ey6-Dai-0tyuvwpE1UrpBQr0YazTkz852z5MQ6S0nylkPGgZfvxmx8RJMJEEUGq4w3BZwkpxyaOs2BF6-TsxBGAChzUZwmf9brvOCsdSGm91EbHSd2adFMQQfmBnZHv45ko0bDtnvyeJiWrm63bPO9Z2h7djXXED1G2k1scJ59od9mYlcad9YF6tnt0UR9MMRuJzLuAdk3jHr2DOzH3jH0xLYebTgYtDHdWDJ6p7t5XFvW7rXFi-TVgCbQm7_1PLm_Xm_bz-nN10-b9vImVQIKSLGrVE5lTlVFZVOXdd3RDKQDGMq6KxTxHniFQ62KvO9FzXNadYjNqhPUKxD5eZI_-yrvQvA0yIPXD-gnyUEuaOUoF7RyQSthJRe0s-rDs4rm0x41eRnU_J2iXntSUfZOv6D_-I9eGW21QvOTJgqjO_o5jiC5DEKCvFuCXHIUBQiomsXg_f8NXlz_BE84sNk
ContentType Journal Article
Copyright 2025
Copyright_xml – notice: 2025
DBID AAYXX
CITATION
DOI 10.1016/j.jval.2025.04.1950
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
Public Health
EndPage S127
ExternalDocumentID 10_1016_j_jval_2025_04_1950
S1098301525020790
1_s2_0_S1098301525020790
GroupedDBID ---
--K
--M
.1-
.3N
.FO
.GA
.Y3
.~1
0R~
10A
123
1OC
1P~
1~.
29Q
31~
36B
4.4
44B
457
4G.
51W
51X
52N
52P
52R
52S
52X
53G
5LA
5VS
66C
6PF
7-5
7PT
8-1
8P~
8UM
AAEDT
AAEDW
AAFJI
AAFWJ
AAIKJ
AAKOC
AALRI
AAMMB
AAOAW
AAPFB
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABCQN
ABDBF
ABEML
ABIVO
ABJNI
ABMAC
ABMMH
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACUHS
ACVFH
ACXQS
ADBBV
ADCNI
ADEZE
ADFHU
ADMUD
ADNMO
ADVLN
AEBSH
AEFGJ
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AEYQN
AFBPY
AFEBI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AFZJQ
AGHFR
AGQPQ
AGTHC
AGUBO
AGXDD
AGYEJ
AIDQK
AIDYY
AIEXJ
AIGII
AIIAU
AIIUN
AIKHN
AITUG
AJAOE
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AOMHK
APXCP
ASPBG
AVARZ
AVWKF
AXJTR
AXLSJ
AZFZN
BAWUL
BFHJK
BKOJK
BLXMC
BNPGV
BY8
CAG
CO8
COF
CS3
DCZOG
DIK
DU5
EAD
EAP
EBS
EFJIC
EFKBS
EFLBG
EJD
EMB
EMK
EMOBN
ESX
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
GBLVA
HF~
HVGLF
HZI
HZ~
IHE
IXB
KOM
LH4
M41
MO0
N9A
O-L
O9-
OAUVE
OIG
OK1
OVD
P-8
P-9
P2P
PC.
PQQKQ
PRBVW
Q38
QB0
R2-
ROL
SDF
SEL
SES
SPCBC
SSB
SSF
SSH
SSO
SSZ
SV3
T5K
TEORI
TUS
W99
WIN
WYUIH
XG1
YFH
Z5R
~G-
~HD
AAYXX
ALUQN
CITATION
O8X
ID FETCH-LOGICAL-c2050-ab7c3e63e77e698688be101b00f68b5ce1d017af8c53dd2813e4baa94b2edc023
ISSN 1098-3015
IngestDate Sat Nov 29 07:24:01 EST 2025
Sat Oct 25 17:39:12 EDT 2025
Sun Oct 19 01:22:31 EDT 2025
Sat Oct 25 11:09:27 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2050-ab7c3e63e77e698688be101b00f68b5ce1d017af8c53dd2813e4baa94b2edc023
ParticipantIDs crossref_primary_10_1016_j_jval_2025_04_1950
elsevier_sciencedirect_doi_10_1016_j_jval_2025_04_1950
elsevier_clinicalkeyesjournals_1_s2_0_S1098301525020790
elsevier_clinicalkey_doi_10_1016_j_jval_2025_04_1950
PublicationCentury 2000
PublicationDate July 2025
PublicationDateYYYYMMDD 2025-07-01
PublicationDate_xml – month: 07
  year: 2025
  text: July 2025
PublicationDecade 2020
PublicationTitle Value in health
PublicationYear 2025
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0006325
Score 2.4310458
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage S126
SubjectTerms Internal Medicine
Public Health
Title EE351 Cost-Utility Analysis of Sequential Therapy of iCT IRd and DRd strategy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant-Ineligible in China
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1098301525020790
https://www.clinicalkey.es/playcontent/1-s2.0-S1098301525020790
https://dx.doi.org/10.1016/j.jval.2025.04.1950
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  issn: 1098-3015
  databaseCode: AIEXJ
  dateStart: 20210201
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: https://www.sciencedirect.com
  omitProxy: false
  ssIdentifier: ssj0006325
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZKhxAvCAaIcpMf0F7WTIlzsfM4TUUUqVNFO1aerFyc0apLpqWdlr_DL-GncWzHSdAqbhIvaesqidXv6zkn1nc-I_Qu8VmcOUFsEY-Glhf5xIogk1lhFsQuY14cBbHabIKenrLFIpz2et9NL8zNmuY5u70Nr_4r1DAGYMvW2b-Au7koDMB7AB2OADsc_wj40cj1HfiflxvrbLNUVXbXeWSmtNObpe7Ll44CyjXiZH44_pRqYTK8ltq0Vqs5IRCuKwiOSpQHBerEiBAnlVgXl5H0-V-qTrnzr8WhlJJpy_Q1oGaNcyV6lg1assHQbNdtCuLP0XqrvtENmc069rbQK_Z5VdS5VYqEIjX6BYbiohUm6Mh5LuTGJBc7hi9Neq5XN4jfKGHrJTfTdvOTKtSRJqgQmfxuGCesQ9duTJ45JOjkd_hId-YOvYyxOloB5kdyLtIDV-6S26bKRsA4k1OQM4AKktg0tO-hPUL9kPXR3vF4tPjYVAOBqzb-baZsnK-UxvDOrXZXR52KZ_4YPaofVfCxptgT1BP5PnowqcUY--hgqm3PqyGet1185RAf4GlriF49Rd8UJXGXkthQEhcZbilZX6iSo0BJDJTEQEkMlMSGkhgoiRUlcUNJbCiJa0piQ0kMlMRASbyTkniZY0XJZ-js_Wh-8sGq9waxEmL7thXFNHFF4ApKRRCygLFYwI8KSSQLWOwnwkkh10QZS3w3TQlzXAFxJwq9mIg0gUL1OernRS5eIJyGUCUnJPEjeBSKpBlT4tAsZUlGUy-zgwEaGkz4lbaA4UYbueISQi4h5LbHJYQD5BncuOluhnzMgWa_Po3uOk2UdWgpucNLwm1-h3oDFDRn1mWzLod_d8uX_zbTV-hh-099jfqb6614g-4nN5tlef225v8PfkPpTg
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EE351+Cost-Utility+Analysis+of+Sequential+Therapy+of+iCT+IRd+and+DRd+strategy+for+Newly+Diagnosed+Multiple+Myeloma+Patients+Who+are+Transplant-Ineligible+in+China&rft.jtitle=Value+in+health&rft.au=Zuo%2C+Genyong&rft.au=Gao%2C+Yongbo&rft.au=Chen%2C+Wendong&rft.au=Chen%2C+Wenming&rft.date=2025-07-01&rft.pub=Elsevier+Inc&rft.issn=1098-3015&rft.volume=28&rft.issue=6&rft.spage=S126&rft.epage=S127&rft_id=info:doi/10.1016%2Fj.jval.2025.04.1950&rft.externalDocID=S1098301525020790
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301525X00073%2Fcov150h.gif